Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastat...
Main Authors: | Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms12624 |
Similar Items
-
Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer—A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research
by: Natalie Zwing, et al.
Published: (2020-10-01) -
Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01) -
A Unique Case of Atezolizumab-Induced Autoimmune Diabetes
by: Mimi Wong, MBBS, et al.
Published: (2020-01-01) -
Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01) -
Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab
by: Lardinois Benjamin, et al.
Published: (2021-07-01)